HIGHLIGHTS
- who: Tobias Kiesslich and Daniel Neureiter from the (UNIVERSITY) have published the research work: Can We Efficiently Target HDAC in Cancer?, in the Journal: Cancers 2022, 14, 4058. of 16/08/2022
SUMMARY
Regarding the knowledge of the role of HDACs in human carcinogenesis, more than thirty years of developing HDAC inhibitors have passed since the first report of a potent zinc-dependent histone deacetylase. Prior to epigenetic therapy, the proteome and phosphoproteome profiling of the AML responders/non-responders cases revealed significant difference in processes of neutrophil degranulation/differentiation, M phase regulation . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.